Back to basics: APTT indications, limitations, preanalytic pitfalls and mixing study essentials

Activated thromboplastin time (aPTT) plays a pivotal role in evaluating hemostasis, primarily targeting the intrinsic and common coagulation pathways and proving crucial information in monitoring unfractionated heparin. It is essential for identifying clotting factor deficiencies, like hemophilia, detecting lupus anticoagulant, and monitoring heparin therapy.

However, aPTT’s utility is tempered by inherent limitations and methodological intricacies, demanding careful consideration during result interpretation. Diverse variables, from sample collection nuances to equipment calibration and patient-specific factors, complicate result standardization across different clinical contexts.

Addressing these challenges, mixing studies have emerged as a complementary strategy, involving the combination of patient and normal plasma. These studies are instrumental in discriminating between factor deficiencies and the presence of inhibitors such as lupus anticoagulants or factor-specific inhibitors.

A nuanced understanding of the inherent limitations and methodological intricacies of aPTT is imperative for accurate and clinically relevant result interpretation. The incorporation of mixing studies enriches diagnostic acumen by facilitating discrimination between factor deficiencies and the presence of inhibitors. The amalgamation of aPTT results with clinical context and supplementary assays remains paramount for a comprehensive and nuanced assessment of a patient’s coagulation profile.
During this webinar, clinicians, clinical pathologists, PhDs, clinical laboratory technicians and students will have the opportunity to find out on the aPTT principle, indications, interpretation and pitfalls, based on the experience of Dr Dorothy Adcock.